Skip to content

Effectiveness of episodic-future-thinking training in reducing symptoms of co-morbid generalized anxiety disorder and persistent depressive disorder through decreasing emotional contrast avoidance

Evaluation of the effectiveness of episodic-future-thinking training in reducing anxiety and depression symptoms in patients with co-morbid generalized anxiety disorder and persistent depressive disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250909067199N1
Enrollment
32
Registered
2025-09-22
Start date
2025-10-21
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Generalized anxiety disorder. Condition 2: Persistent depressive disorder. Anxiety that is generalized and persistent but not restricted to, or even strongly predominating in, any particular environmental circumstances (i.e. it is "free-floating"). The dominant symptoms are variable but include complaints of persistent nervousne A chronic depression of mood, lasting at least several years, which is not sufficiently severe, or in which individual episodes are not sufficiently prolo

Interventions

Intervention 1: Intervention group: Receiving four one-hour, in-person, group sessions of episodic-future-thinking training along with in-session practice and two practice worksheets for use between s

Sponsors

Kharazmi University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: All people with co-morbid generalized anxiety disorder and persistent depressive disorder Age between 18 to 55 years old Ability to read and write in Farsi language

Exclusion criteria

Exclusion criteria: Con-current participation in a psychological treatment program for anxiety and/or depression Receiving a diagnosis of psychotic disorder, substance use disorder, severe personality disorder (such as borderline personality disorder), and/or the bipolar disorder spectrum or having had any of these conditions in the past Having received any form of psychological treatment during the last three months Concurrent participation in a pharmacological treatment program for anxiety and/or depression with variable medication dosage Having any medical condition that affects anxiety and depression (including cancer, chronic pain, thyroid problems, lupus, diabetes, HIV, multiple sclerosis, heart problems, and asthma)

Design outcomes

Primary

MeasureTime frame
The percentage of individuals scoring below 10 on the seven-item Generalized Anxiety Disorder questionnaire (GAD-7). Timepoint: Pre-intervention - Post-intervention - 2-month follow-up. Method of measurement: The seven-item Generalized Anxiety Disorder questionnaire (GAD-7).;The percentage of individuals scoring below 10 on the nine-item Patient Health Questionnaire (PHQ-9). Timepoint: Pre-intervention - Post-intervention - 2-month follow-up. Method of measurement: The nine-item Patient Health Questionnaire (PHQ-9).

Secondary

MeasureTime frame
Percentage of individuals scoring below 50 on the Emotion Contrast Avoidance Questionnaire. Timepoint: Pre-intervention - sessions 2-4 - Post-intervention - 2-month follow-up. Method of measurement: Emotion Contrast Avoidance Questionnaire.;Percentage of individuals scoring above 10 on the episodic future thinking test. Timepoint: Pre-intervention - sessions 2-4 - Post-intervention - 2-month follow-up. Method of measurement: Episodic future thinking test.;Percentage of individuals scoring below 20 on the work and social adjustment scale. Timepoint: Pre-intervention - Post-intervention - 2-month follow-up. Method of measurement: The work and social adjustment scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShiva Jamshidi

Kharazmi Univeristy

shiva.jamshidi@khu.ac.ir+98 21 4451 8702

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026